The role of CR2 in autoimmunity

Autoimmunity

Volumn 39, Issue 5, 2006, Pages 357-366

  Isaák, Andrea ^a   Prechl, József ^a   Gergely, János ^a   Erdei, Anna ^a  

^a EÖTVÖS LORÁND UNIVERSITY   (Hungary)

Author keywords

Autoimmunity; B cells; Complement; CR2; T cells; Tolerance

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; CD19 ANTIGEN; CD23 ANTIGEN; CD81 ANTIGEN; CD86 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3 RECEPTOR; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C3D RECEPTOR; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C4D; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PROTEIN BCL 2;

ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; CELLULAR DISTRIBUTION; COMPLEMENT ACTIVATION; COMPLEX FORMATION; GENE DISRUPTION; GENE LOCUS; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INNATE IMMUNITY; JUVENILE RHEUMATOID ARTHRITIS; MYOCARDITIS; NONHUMAN; OPSONIZATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE ACTIVATION;

ANIMALS; AUTOIMMUNITY; B-LYMPHOCYTES; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNE TOLERANCE; INFLAMMATION; MICE; MODELS, ANIMAL; RECEPTORS, COMPLEMENT 3D;

EID: 33747697069     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930600739001     Document Type: Article

References (93)

1. Molina, H and Kinoshita, T and Inoue, K and Carel, JC and Holers, VM. (1990) A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2 J Immunol, 145, pp. 2974-2983.
2. Fingeroth, JD and Weis, JJ and Tedder, TF and Strominger, JL and Biro, PA and Fearon, DT. (1984) Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2 Proc Natl Acad Sci USA, 81, pp.4510-4514.
3. Aubry, JP and Pochon, S and Graber, P and Jansen, KU and Bonnefoy, JY. (1992) CD21 is a ligand for CD23 and regulates IgE production Nature, 358, pp.505-507.
4. Delcayre, AX and Salas, F and Mathur, S and Kovats, K and Lotz, M and Lernhardt, W. (1991) Epstein Barr virus/complement C3d receptor is an interferon alpha receptor EMBO J, 10, pp.919-926.
5. Bouillie, S and Barel, M and Drane, P and Cassinat, B and Balbo, M and Holers, VM and Frade, R. (1995) Epstein-Barr virus/C3d receptor (CR2, CD21) activated by its extracellular ligands regulates pp105 phosphorylation through two distinct pathways Eur J Immunol, 25, pp.2661-2667.
6. Matsumoto, AK and Kopicky-Burd, J and Carter, RH and Tuveson, DA and Tedder, TF and Fearon, DT. (1991) Intersection of the complement and immune systems: A signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19 J Exp Med, 173, pp.55-64.
7. Tuveson, DA and Ahearn, JM and Matsumoto, AK and Fearon, DT. (1991) Molecular interactions of complement receptors on B lymphocytes: A CR1/ CR2 complex distinct from the CR2/CD19 complex J Exp Med, 173, pp.1083-1089.
8. Fujisaku, A and Harley, JB and Frank, MB and Gruner, BA and Frazier, B and Holers, VM. (1989) Genomic organization and polymorphisms of the human C3d/Epstein-Barr virus receptor J Biol Chem, 264, pp.2118-2125.
9. Takahashi, K and Kozono, Y and Waldschmidt, TJ and Berthiaume, D and Quigg, RJ and Baron, A and Holers, VM. (1997) Mouse complement receptors type 1 (CR1;CD35) and type 2 (CR2;CD21): Expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice J Immunol, 159, pp.1557-1569.
10. Tedder, TF and Clement, LT and Cooper, MD. (1984) Expression of C3d receptors during human B cell differentiation: Immunofluorescence analysis with the HB-5 monoclonal antibody J Immunol, 133, pp.678-683.
11. Uckun, FM. (1990) Regulation of human B-cell ontogeny Blood, 76, pp.1908-1923.
12. Timens, W and Boes, A and Poppema, S. (1989) Human marginal zone B cells are not an activated B cell subset: Strong expression of CD21 as a putative mediator for rapid B cell activation Eur J Immunol, 19, pp.2163-2166.
13. Carter, RH and Spycher, MO and Ng, YC and Hoffman, R and Fearon, DT. (1988) Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes J Immunol, 141, pp.457-463.
14. Luxembourg, AT and Cooper, NR. (1994) Modulation of signaling via the B cell antigen receptor by CD21, the receptor for C3dg and EBV J Immunol, 153, pp.4448-4457.
15. Dempsey, PW and Allison, ME and Akkaraju, S and Goodnow, CC and Fearon, DT. (1996) C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity Science, 271, pp.348-350.
16. Lee, Y and Haas, KM and Gor, DO and Ding, X and Karp, DR and Greenspan, NS and Poe, JC and Tedder, TF. (2005) Complement component C3d-antigen complexes can either augment or inhibit B lymphocyte activation and humoral immunity in mice depending on the degree of CD21/CD19 complex engagement J Immunol, 175, pp.8011-8023.
17. Kozono, Y and Abe, R and Kozono, H and Kelly, RG and Azuma, T and Holers, VM. (1998) Cross-linking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cells J Immunol, 160, pp.1565-1572.
18. Prechl, J and Baiu, DC and Horvath, A and Erdei, A. (2002) Modeling the presentation of C3d-coated antigen by B lymphocytes: Enhancement by CR1/ 2-BCR co-ligation is selective for the co-ligating antigen Int Immunol, 14, pp.241-247.
19. Cherukuri, A and Cheng, PC and Sohn, HW and Pierce, SK. (2001) The CD19/ CD21 complex functions to prolong B cell antigen receptor signaling from lipid rafts Immunity, 14, pp.169-179.
20. Erdei, A and Melchers, F and Schulz, T and Dierich, M. (1985) The action of human C3 in soluble or cross-linked form with resting and activated murine B lymphocytes Eur J Immunol, 15, pp.184-188.
21. Melchers, F. and Erdei, A. and Schulz, T. and Dierich, M.P. (1985) Growth control of activated, synchronized murine B cells by the C3d fragment of human complement Nature, 317, pp.264-267.
22. Croix, DA and Ahearn, JM and Rosengard, AM and Han, S and Kelsoe, G and Ma, M and Carroll, MC. (1996) Antibody response to a T-dependent antigen requires B cell expression of complement receptors J Exp Med, 183, pp.1857-1864.
23. Fang, Y and Xu, C and Fu, YX and Holers, VM and Molina, H. (1998) Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response J Immunol, 160, pp.5273-5279.
24. Fischer, MB and Goerg, S and Shen, L and Prodeus, AP and Goodnow, CC and Kelsoe, G and Carroll, MC. (1998) Dependence of germinal center B cells on expression of CD21/CD35 for survival Science, 280, pp.582-585.
25. Reid, RR and Woodcock, S and Shimabukuro-Vornhagen, A and Austen, WG, Jr and Kobzik, L and Zhang, M and Hechtman, HB and Moore, FD, Jr and Carroll, MC. (2002) Functional activity of natural antibody is altered in Cr2-deficient mice J Immunol, 169, pp.5433-5440.
26. Ahearn, JM and Fischer, MB and Croix, D and Goerg, S and Ma, M and Xia, J and Zhou, X and Howard, RG and Rothstein, TL and Carroll, MC. (1996) Disruption of the CR2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen Immunity, 4, pp.251-262.
27. Prodeus, AP and Goerg, S and Shen, LM and Pozdnyakova, OO and Chu, L and Alicot, EM and Goodnow, CC and Carroll, MC. (1998) A critical role for complement in maintenance of self-tolerance Immunity, 9, pp. 721-731.
28. Del Nagro, CJ and Kolla, RV and Rickert, RC. (2005) A critical role for complement C3d and the B cell coreceptor (CD19/CD21) complex in the initiation of inflammatory arthritis J Immunol, 175, pp.5379-5389.
29. Kaya, Z and Afanasyeva, M and Wang, Y and Dohmen, KM and Schlichting, J and Tretter, T and Fairweather, D and Holers, VM and Rose, NR. (2001) Contribution of the innate immune system to autoimmune myocarditis: A role for complement Nat Immunol, 2, pp.739-745.
30. Meyer, O and Hauptmann, G and Tappeiner, G and Ochs, HD and Mascart-Lemone, F. (1985) Genetic deficiency of C4, C2 or C1q and lupus syndromes. Association with anti-Ro (SS-A) antibodies Clin Exp Immunol, 62, pp.678-684.
31. Morgan, BP and Walport, MJ. (1991) Complement deficiency and disease Immunol Today, 12, pp.301-306.
32. Paul, E and Pozdnyakova, OO and Mitchell, E and Carroll, MC. (2002) Anti-DNA autoreactivity in C4-deficient mice Eur J Immunol, 32, pp.2672-2679.
33. Sekine, H and Reilly, CM and Molano, ID and Garnier, G and Circolo, A and Ruiz, P and Holers, VM and Boackle, SA and Gilkeson, GS. (2001) Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice J Immunol, 166, pp.6444-6451.
34. Boackle, SA and Holers, VM and Chen, X and Szakonyi, G and Karp, DR and Wakeland, EK and Morel, L. (2001) CR2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein Immunity, 15, pp. 775-785.
35. Carsetti, R and Kohler, G and Lamers, MC. (1995) Transitional B cells are the target of negative selection in the B cell compartment J Exp Med, 181, pp.2129-2140.
36. Norvell, A and Mandik, L and Monroe, JG. (1995) Engagement of the antigen-receptor on immature murine B lymphocytes results in death by apoptosis J Immunol, 154, pp.4404-4413.
37. Gorelik, L and Cutler, AH and Thill, G and Miklasz, SD and Shea, DE and Ambrose, C and Bixler, SA and Su, L and Scott, ML and Kalled, SL. (2004) Cutting edge: BAFF regulates CD21/35 and CD23 expression independent of its B cell survival function J Immunol, 172, pp.762-766.
38. Thien, M and Phan, TG and Gardam, S and Amesbury, M and Basten, A and Mackay, F and Brink, R. (2004) Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches Immunity, 20, pp.785-798.
39. Kim, SJ and Gershov, D and Ma, X and Brot, N and Elkon, KB. (2002) I-PLA(2) activation during apoptosis promotes the exposure of membrane lysophosphatidylcholine leading to binding by natural immunoglobulin M antibodies and complement activation J Exp Med, 196, pp.655-665.
40. Grimaldi, CM and Michael, DJ and Diamond, B. (2001) Cutting edge: Expansion and activation of a population of autoreactive marginal zone B cells in a model of estrogen-induced lupus J Immunol, 167, pp.1886-1890.
41. Zeng, D and Lee, MK and Tung, J and Brendolan, A and Strober, S. (2000) Cutting edge: A role for CD1 in the pathogenesis of lupus in NZB/NZW mice J Immunol, 164, pp.5000-5004.
42. Song, H and Cerny, J. (2003) Functional heterogeneity of marginal zone B cells revealed by their ability to generate both early antibody-forming cells and germinal centers with hypermutation and memory in response to a T-dependent antigen J Exp Med, 198, pp.1923-1935.
43. Attanavanich, K and Kearney, JF. (2004) Marginal zone, but not follicular B cells, are potent activators of naive CD4 T cells J Immunol, 172, pp.803-811.
44. Cariappa, A and Tang, M and Parng, C and Nebelitskiy, E and Carroll, M and Georgopoulos, K and Pillai, S. (2001) The follicular versus marginal zone B lymphocyte cell fate decision is regulated by Aiolos, Btk, and CD21 Immunity, 14, pp.603-615.
45. Gatto, D and Pfister, T and Jegerlehner, A and Martin, SW and Kopf, M and Bachmann, MF. (2005) Complement receptors regulate differentiation of bone marrow plasma cell precursors expressing transcription factors Blimp-1 and XBP-1 J Exp Med, 201, pp.993-1005.
46. Brunner, C and Marinkovic, D and Klein, J and Samardzic, T and Nitschke, L and Wirth, T. (2003) B cell-specific transgenic expression of Bcl2 rescues early B lymphopoiesis but not B cell responses in BOB.1/ OBF.1-deficient mice J Exp Med, 197, pp.1205-1211.
47. Fang, Y and Xu, C and Fu, YX and Holers, VM and Molina, H. (1998) Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response J Immunol, 160, pp.5273-5279.
48. Barrington, RA and Zhang, M and Zhong, X and Jonsson, H and Holodick, N and Cherukuri, A and Pierce, SK and Rothstein, TL and Carroll, MC. (2005) CD21/CD19 coreceptor signaling promotes B cell survival during primary immune responses J Immunol, 175, pp.2859-2867.
49. Gatto, D and Pfister, T and Jegerlehner, A and Martin, SW and Kopf, M and Bachmann, MF. (2005) Complement receptors regulate differentiation of bone marrow plasma cell precursors expressing transcription factors Blimp-1 and XBP-1 J Exp Med, 201, pp.993-1005.
50. Kerekes, K and Prechl, J and Bajtay, Z and Jozsi, M and Erdei, A. (1998) A further link between innate and adaptive immunity: C3 deposition on antigen-presenting cells enhances the proliferation of antigen-specific T cells Int Immunol, 10, pp.1923-1930.
51. Gatto, D and Pfister, T and Jegerlehner, A and Martin, SW and Kopf, M and Bachmann, MF. (2005) Complement receptors regulate differentiation of bone marrow plasma cell precursors expressing transcription factors Blimp-1 and XBP-1 J Exp Med, 201, pp.993-1005.
52. Barrington, RA and Pozdnyakova, O and Zafari, MR and Benjamin, CD and Carroll, MC. (2002) B lymphocyte memory: Role of stromal cell complement and FcgammaRIIB receptors J Exp Med, 196, pp.1189-1199.
53. Noorchashm, H and Moore, DJ and Lieu, YK and Noorchashm, N and Schlachterman, A and Song, HK and Barker, CF and Naji, A. (1999) Contribution of the innate immune system to autoimmune diabetes: A role for the CR1/CR2 complement receptors Cell Immunol, 195, pp.75-79.
54. Jozsi, M and Prechl, J and Bajtay, Z and Erdei, A. (2002) Complement receptor type 1 (CD35) mediates inhibitory signals in human B lymphocytes J Immunol, 168, pp.2782-2788.
55. Wagner, C. and Ochmann, C. and Schoels, M. and Giese, T. and Stegmaier, S. and Richter, R. and Hug, F. and Hansch, G.M. (2006) The complement receptor 1, CR1 (CD35), mediates inhibitory signals in human T-lymphocytes Mol Immunol, 43, pp.643-651.
56. Marquart, HV and Svendsen, A and Rasmussen, JM and Nielsen, CH and Junker, P and Svehag, SE and Leslie, RG. (1995) Complement receptor expression and activation of the complement cascade on B lymphocytes from patients with systemic lupus erythematosus (SLE) Clin Exp Immunol, 101, pp.60-65.
57. Wilson, JG and Ratnoff, WD and Schur, PH and Fearon, DT. (1986) Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus Arthritis Rheum, 29, pp.739-747.
58. Illges, H and Braun, M and Peter, HH and Melchers, I. (2000) Reduced expression of the complement receptor type 2 (CR2, CD21) by synovial fluid B and T lymphocytes Clin Exp Immunol, 122, pp.270-276.
59. Mitchell, JP and Enyedy, EJ and Nambiar, MP and Lees, A and Tsokos, GC. (2002) Engagement of complement receptor 2 on the surface of B cells from patients with systemic lupus erythematosus contributes to the increased responsiveness to antigen stimulation Lupus, 11, pp.299-303.
60. Ling, N and Hansel, T and Richardson, P and Brown, B. (1991) Cellular origins of serum complement receptor type 2 in normal individuals and in hypogammaglobulinaemia Clin Exp Immunol, 84, pp.16-22.
61. Liu, YJ and Xu, J and de, BO and Parham, CL and Grouard, G and Djossou, O and de Saint-Vis, B and Lebecque, S and Banchereau, J and Moore, KW. (1997) Follicular dendritic cells specifically express the long CR2/CD21 isoform J Exp Med 185, pp.165-170.
62. Masilamani, M and Kassahn, D and Mikkat, S and Glocker, MO and Illges, H. (2003) B cell activation leads to shedding of complement receptor type II (CR2/CD21) Eur J Immunol, 33, pp.2391-2397.
63. Fremeaux-Bacchi, V and Bernard, I and Maillet, F and Mani, JC and Fontaine, M and Bonnefoy, JY and Kazatchkine, MD and Fischer, E. (1996) Human lymphocytes shed a soluble form of CD21 (the C3dg/Epstein-Barr virus receptor, CR2) that binds iC3b and CD23 Eur J Immunol, 26, pp.1497-1503.
64. Illges, H and Braun, M and Peter, HH and Melchers, I. (1997) Analysis of the human CD21 transcription unit reveals differential splicing of exon 11 in mature transcripts and excludes alternative splicing as the mechanism causing solubilization of CD21 Mol Immunol, 34, pp.683-693.
65. Masilamani, M and Nowack, R and Witte, T and Schlesier, M and Warnatz, K and Glocker, MO and Peter, HH and Illges, H. (2004) Reduction of soluble complement receptor 2/CD21 in systemic lupus erythomatosus and Sjogren's syndrome but not juvenile arthritis Scand J Immunol, 60, pp.625-630.
66. Masilamani, M and von, KJ and Illges, H. (2004) Decreased levels of serum soluble complement receptor-II (CR2/CD21) in patients with rheumatoid arthritis Rheumatology (Oxford), 43, pp.186-190.
67. Grottenthaler, T and Kempis, J and Goldacker, S and Illges, H. (2006) Soluble CD21 in sera and synovial fluid of arthritic patients Rheumatol Int, 26, pp.240-243.
68. Arora, V and Verma, J and Dutta, R and Marwah, V and Kumar, A and Das, N. (2004) Reduced complement receptor 1 (CR1, CD35) transcription in systemic lupus erythematosus Mol. Immunol, 41, pp.449-456.
69. Fischer, E and Delibrias, C and Kazatchkine, MD. (1991) Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes J Immunol, 146, pp.865-869.
70. Tsoukas, CD and Lambris, JD. (1988) Expression of CR2/EBV receptors on human thymocytes detected by monoclonal antibodies Eur J Immunol, 18, pp.1299-1302.
71. Sinha, SK and Todd, SC and Hedrick, JA and Speiser, CL and Lambris, JD and Tsoukas, CD. (1993) Characterization of the EBV/C3d receptor on the human Jurkat T cell line: Evidence for a novel transcript J Immunol, 150, pp.5311-5320.
72. Braun, M and Melchers, I and Peter, HH and Illges, H. (1998) Human B and T lymphocytes have similar amounts of CD21 mRNA, but differ in surface expression of the CD21 glycoprotein Int Immunol, 10, pp.1197-1202.
73. Levy, E and Ambrus, J and Kahl, L and Molina, H and Tung, K and Holers, VM. (1992) T lymphocyte expression of complement receptor 2 (CR2/CD21): A role in adhesive cell-cell interactions and dysregulation in a patient with systemic lupus erythematosus (SLE) Clin Exp Immunol, 90, pp.235-244.
74. Marquart, HV and Svehag, SE and Leslie, RG. (1994) CR2 is the primary acceptor site for C3 during alternative pathway activation of complement on human peripheral B lymphocytes J Immunol, 153, pp.307-315.
75. Sato, S and Fujimoto, M and Hasegawa, M and Takehara, K. (2004) Altered blood B lymphocyte homeostasis in systemic sclerosis: Expanded naive B cells and diminished but activated memory B cells Arthritis Rheum, 50, pp.1918-1927.
76. Odendahl, M and Jacobi, A and Hansen, A and Feist, E and Hiepe, F and Burmester, GR and Lipsky, PE and Radbruch, A and Dorner, T. (2000) Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus J Immunol, 165, pp.5970-5979.
77. McCune, WJ and Golbus, J and Zeldes, W and Bohlke, P and Dunne, R and Fox, DA. (1988) Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus N Engl J Med, 318, pp.1423-1431.
78. Cepok, S and Rosche, B and Grummel, V and Vogel, F and Zhou, D and Sayn, J and Sommer, N and Hartung, HP and Hemmer, B. (2005) Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis Brain, 128, pp.1667-1676.
79. Mantovani, L and Wilder, RL and Casali, P. (1993) Human rheumatoid B-1a (CD5+B) cells make somatically hypermutated high affinity IgM rheumatoid factors J Immunol, 151, pp.473-488.
80. Randen, I and Mellbye, OJ and Forre, O and Natvig, JB. (1995) The identification of germinal centres and follicular dendritic cell networks in rheumatoid synovial tissue Scand J Immunol, 41, pp.481-486.
81. Andrews, PA and Zhou, W and Sacks, SH. (1995) Tissue synthesis of complement as an immune regulator Mol Med Today, 1, pp.202-207.
82. Colten, HR and Ooi, YM and Edelson, PJ. (1979) Synthesis and secretion of complement proteins by macrophages Ann N Y Acad Sci, 332, pp.482-490.
83. Laufer, J and Katz, Y and Passwell, JH. (2001) Extrahepatic synthesis of complement proteins in inflammation Mol Immunol, 38, pp.221-229.
84. Olmez, U and Garred, P and Mollnes, TE and Harboe, M and Berntzen, HB and Munthe, E. (1991) C3 activation products, C3 containing immune complexes, the terminal complement complex and native C9 in patients with rheumatoid arthritis Scand J Rheumatol, 20, pp.183-189.
85. Kemp, PA and Spragg, JH and Brown, JC and Morgan, BP and Gunn, CA and Taylor, PW. (1992) Immunohistochemical determination of complement activation in joint tissues of patients with rheumatoid arthritis and osteoarthritis using neoantigen-specific monoclonal antibodies J Clin Lab Immunol, 37, pp.147-162.
86. Muso, E and Sekita, K and Doi, T and Kuwahara, T and Yoshida, H and Tamura, T and Kawai, C and Hamashima, Y. (1984) Immunopathological correlation between mesangial C3d-deposition and C3d-fixing circulating immune complexes in lupus nephritis Clin Immunol Immunopathol, 32, pp.351-358.
87. Pers, JO and Daridon, C and Devauchelle, V and Jousse, S and Saraux, A and Jamin, C and Youinou, P. (2005) BAFF overexpression is associated with autoantibody production in autoimmune diseases Ann N Y Acad Sci, 1050, pp.34-39.
88. Boackle, SA and Culhane, KK and Brown, JM and Haas, M and Bao, L and Quigg, RJ and Holers, VM. (2004) CR1/CR2 deficiency alters IgG3 autoantibody production and IgA glomerular deposition in the MRL/lpr model of SLE Autoimmunity, 37, pp.111-123.
89. Noorchashm, H and Moore, DJ and Lieu, YK and Noorchashm, N and Schlachterman, A and Song, HK and Barker, CF and Naji, A. (1999) Contribution of the innate immune system to autoimmune diabetes: A role for the CR1/CR2 complement receptors Cell Immunol, 195, pp.75-79.
90. Kaya, Z and Afanasyeva, M and Wang, Y and Dohmen, KM and Schlichting, J and Tretter, T and Fairweather, D and Holers, VM and Rose, NR. (2001) Contribution of the innate immune system to autoimmune myocarditis: A role for complement Nat Immunol, 2, pp.739-745.
91. Grottenthaler, T and Kempis, J and Goldacker, S and Illges, H. (2006) Soluble CD21 in sera and synovial fluid of arthritic patients Rheumatol Int, 26, pp.240-243.
92. Masilamani, M and von, KJ and Illges, H. (2004) Decreased levels of serum soluble complement receptor-II (CR2/CD21) in patients with rheumatoid arthritis Rheumatology (Oxford), 43, pp.186-190.
93. Masilamani, M and Nowack, R and Witte, T and Schlesier, M and Warnatz, K and Glocker, MO and Peter, HH and Illges, H. (2004) Reduction of soluble complement receptor 2/CD21 in systemic lupus erythomatosus and Sjogren's syndrome but not juvenile arthritis Scand J Immunol, 60, pp.625-630.